Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Caplin Point Laboratories is a Chennai-based pharmaceutical company with an unusual model: dominant, distribution-deep generics franchises in Latin American and West African frontier markets (Guatemala, El Salvador, Ecuador etc.) selling branded generics with cash-rich working capital, plus a growing US injectables business through subsidiary Caplin Steriles. It is backward-integrating into APIs and expanding sterile capacity; the model has delivered consistently high margins and negative-working-capital-like cash generation in LatAm.
A niche mid-cap with leading generic pharma positions in Central/South American frontier markets.
Caplin Point Laboratories Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Caplin Point Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 84.36 | 70.57 | 60.19 |
| Book value / share (₹) | 477.74 | 379.79 | 309.00 |
| Return on equity | 17.7% | 19.5% | 19.5% |
| Return on capital employed | 18.8% | 20.0% | 21.0% |
| Operating margin | 31.5% | 30.0% | 29.4% |
| Net margin | 29.7% | 27.9% | 27.2% |
| EBITDA | ₹761 Cr | ₹647 Cr | ₹551 Cr |
| Free cash flow | ₹275 Cr | ₹241 Cr | ₹165 Cr |
| Total debt | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Debt to equity | 0.00 | 0.00 | 0.00 |
| Interest coverage | 790.9 | 952.4 | 638.5 |
| Current ratio | 6.70 | 6.97 | 5.72 |
| Shares outstanding | 7,60,00,000 | 7,60,00,000 | 7,59,50,000 |
Open the full income statement, balance sheet and cash flow for CAPLIPOINT →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.